𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly

✍ Scribed by Marily Theodoropoulou; Maria A. Tichomirowa; Caroline Sievers; Alexander Yassouridis; Thomas Arzberger; Olivier Hougrand; Manuel Deprez; Adrian F. Daly; Patrick Petrossians; Uberto Pagotto; Albert Beckers; Günter K. Stalla

Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
197 KB
Volume
125
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Somatostatin analogs (SSA) with their potent antisecretory and antiproliferative effects are the main medical treatment option for patients with neuroendocrine tumors, such as gastroenteropancreatic and acromegaly‐associated growth hormone secreting pituitary tumors. Although a good portion of acromegalic patients gets normalized after SSA treatment, strict hormonal control is not achieved in a sizeable proportion of these patients. The reasons for this incomplete response to SSA treatment are unclear. We have found that the tumor suppressor ZAC1 (LOT1/PLAGL1) is essential for the antiproliferative effect of SSA in pituitary tumor cells. The aim of the present retrospective cohort study was to determine whether ZAC1 immunoreactivity in archival somatotrophinoma tissue derived from 45 patients with acromegaly routinely pretreated with SSA before surgery, was associated with response to SSA (normalization of GH, IGF‐I and presence of tumor shrinkage). All tumors displayed ZAC1 immunoreactivity [weak (+; n = 15), moderate (++; n = 16) and strong (+++; n = 14)]. A significant positive correlation was found between strong ZAC1 immunoreactivity and IGF‐I normalization and presence of tumor shrinkage after SSA treatment, which was not affected by age at diagnosis, gender or duration of SSA treatment. These in vivo data combined with the antiproliferative properties of ZAC1/Zac1 provide evidence of a mechanistic role for this transcription factor on SSA induced tumor shrinkage and hormone normalization. © 2009 UICC

📜 SIMILAR VOLUMES

Nuclear Maspin expression is associated
Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer
✍ Wolfgang Dietmaier; Marcus Bettstetter; Peter J. Wild; Matthias Woenckhaus; Petr 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 528 KB

## Abstract Maspin, a member of the Serpin protease inhibitor family, is overexpressed in poorly differentiated colorectal tumors and more frequently found in tumors with microsatellite instability. Immunohistochemical nuclear Maspin staining is predominantly seen in tumor cells at the invasion fro

Expression of tumor-associated 90k-antig
Expression of tumor-associated 90k-antigen in human breast cancer: No correlation with prognosis and response to first-line therapy with tamoxifen
✍ John A. Foekens; Jan G. M. Klun; Clara Natoli; Wim L. J. Van Putten; Pia Di Stef 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 614 KB

It has been shown that a 90-kDa protein (90K). with an as yet unknown function, is expressed in the majority of human breast-cancer tissues. In addition, the serum level of this 90K antigen is elevated in a certain proportion of breast-cancer patients, and high serum levels are associated with a poo

The tumor-associated shift in immunoglob
The tumor-associated shift in immunoglobulin G1/G2 is expressed at the messenger RNA level of peripheral blood B lymphocytes in patients with gynecologic malignancies
✍ Peter Felsner; Waltraud Steinschifter; Michaela Fischer; Robert Eferl; Lukas Ken 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 2 views

## Background: Previously, it could be demonstrated that human patients with malignant diseases of various tissues exhibited characteristic and highly significant changes in the serum patterns of immunoglobulin (ig)g subclasses, consisting of a decrease in igg1 and an increase in igg2 relative to t